Melanotan I vs Pinealon
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Melanotan I
Melanotan I (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe sun sensitivity.
Full details →Pinealon
Pinealon is a short synthetic peptide developed from research on the pineal gland. It has shown neuroprotective and cognitive-enhancing properties in animal studies.
Full details →Side-by-Side Comparison
| Aspect | Melanotan I | Pinealon |
|---|---|---|
| Mechanism | Binds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection without UV exposure. | Penetrates cell membranes and interacts with DNA to regulate gene expression related to neuronal survival and function. May support pineal gland function and melatonin production. |
| Typical Dosage | Clinical: 16mg implant every 2 months. Research protocols for tanning typically use 0.5-1mg daily for loading, then maintenance dosing. | Typical dosing: 10-20mg daily, taken in divided doses. Often used in cycles of 10-20 days. |
| Administration | FDA-approved form is a subcutaneous implant. Research use involves subcutaneous injection. Often combined with minimal UV exposure to enhance results. | Can be taken orally (capsules) or sublingually. Best absorbed on an empty stomach. Often combined with other neuroprotective peptides. |
| Side Effects | Nausea (especially initially), facial flushing, fatigue, headache, and darkening of existing moles or freckles. | Generally well-tolerated. Limited reported side effects. May affect sleep patterns initially. |
| Best For |